Trial Profile
A randomized, placebo-controlled, double-blind study to scrutinize the efficacy of Secukinumab in patients with moderate to severe atopic dermatitis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Secukinumab (Primary)
- Indications Atopic dermatitis
- Focus Therapeutic Use
- Acronyms Secu_in_AD; SECU_Trial
- 28 May 2020 Status changed from active, no longer recruiting to completed.
- 29 Jan 2020 Status changed from recruiting to active, no longer recruiting.
- 08 Oct 2019 Planned End Date changed from 1 Jul 2020 to 1 Mar 2021.